Dr Reddy's targets 6-7 million semaglutide pens in FY27
Dr Reddy's Laboratories Ltd has delayed commercial supplies of semaglutide after detecting an impurity during API scale-up validation. The company expects to resolve the issue by September and resume supplies by late October, targeting 6-7 million pens in FY27. There is no impact on patient safety or existing regulatory filings, though inventory at partner OneSource may face a write-down.
*this image is generated using AI for illustrative purposes only.
Dr Reddy's Laboratories Ltd has halted commercial supplies of semaglutide after identifying an impurity issue during the scale-up validation of its active pharmaceutical ingredient (API). The company aims to resume supplies by late October or early November, targeting the delivery of 6 to 7 million pens between Q3 and Q4 of FY27. This development follows a disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, detailing a quality deviation found in the formulation process at its API facility.
Management clarified that the impurity, a degradation detected during the testing of the finished drug product, is linked to the process and reaction of the API scale-up. Consequently, the company must repeat validation with three new batches, a process expected to conclude by the end of September. This timeline assumes successful validation and testing, which includes sterility checks taking up to three weeks. While the API itself met specifications initially, the degradation occurred during formulation, necessitating a halt in production to ensure compliance with cGMP standards.
Impact on Operations and Guidance
The supply disruption will result in a temporary halt of commercial quantities for several months. The company confirmed that there is no recall of product already in the market, as the affected batches were validation lots that were not shipped commercially. However, inventory lying with partner OneSource may require a write-down. Management noted that this event will result in a downside to the sales volumes previously discussed in May and June, though the long-term EBITDA margin target of 20% plus remains unchanged.
| Parameter | Details |
|---|---|
| Issue Identified | API impurity detected during scale-up validation |
| Product Affected | Semaglutide injection |
| Supply Resumption Target | Late October / Early November |
| FY27 Sales Target | 6-7 million pens |
| Patient Safety Impact | None |
| Regulatory Filing Impact | None |
Strategic and Financial Implications
The company emphasized that the issue is isolated to the new scale-up process and does not affect existing global regulatory filings or the supply of semaglutide oral tablets, which use a different API source. Dr Reddy's is currently in a silent period for its Q1FY27 results and will provide further financial details in two weeks. The management remains committed to its long-term partnership with OneSource for fill-finish operations, despite the current delay. Additionally, the company is qualifying an alternate supplier as a backup, though this option is approximately a year away due to the requirement for a pre-approval supplement.
Historical Stock Returns for Dr Reddys Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.34% | -9.24% | -3.91% | +3.62% | -1.69% | +14.04% |
What specific financial impact will the inventory write-down with partner OneSource have on Q1FY27 earnings?
How will the temporary supply disruption affect Dr Reddy's market share in the semaglutide segment against competitors during the hiatus?
What is the contingency plan if the three new validation batches fail to meet sterility checks by the end of September?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
